CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

M amp A news update Smith amp Nephew and Bouygues

Article By: ,  Financial Analyst

Recurring takeover speculation surrounding UK-based medical devices manufacturer, Smith & Nephew, has resurfaced.

That’s certainly helped give the company shares, which are down today, a bit of a lift recently – up around 12% over the last week on the back of that talk.

Reports emerged last week suggesting that US-based, Stryker, was considering a takeover bid for the UK-based company. Stryker is said to have confirmed that it was evaluating a bid, but, isn’t planning to make an offer.

That hasn’t stopped more M&A talk from ensuing: more recently, there’s been chatter that US-based, Medtronic, might have an eye on Smith & Nephew.

That’s aside from Johnson & Johnson, which is said to have made an unsuccessful move on Smith & Nephew a few years ago, and has recently been mentioned as standing to benefit from making a fresh move.

Is there anything for an acquirer to like about Smith & Nephew?

Well, Smith & Nephew does have its attractions.

For starters, the company’s product portfolio includes orthopaedic reconstruction implants for hip, knee and shoulder joints.

That market is expected to enjoy strong growth globally over the next few years, driven – in part – by an aging population. Recent estimates peg the size of that market to grow to around $41bn by 2019, up from $29bn in 2012.

Meanwhile, potential tax benefits have been cited as a possible motivating factor for any US-based acquirer.

All of that’s aside from the fact that Smith & Nephew has a comparatively small market capitalisation and a virtually debt-free balance sheet, which makes it an eminently affordable target for its aforementioned larger rivals.

Certainly, the company’s appeal is there to be seen, and while the current chatter may well be just that, there seems to be some logic to it – and that should help prop up Smith & Nephew’s shares.

Regarding Bouygues…

There’s reportedly been some momentum regarding a potential purchase of the company’s telecoms business (Bouygues Telecom).

Recent reports have suggested that Orange has lined up some banks to evaluate a potential acquisition of Bouygues Telecom.

That follows last month’s news flow that suggested Orange held informal talks with Bouygues regarding acquiring the business.

Certainly, such a tie-up faces potential regulatory hurdles, meanwhile, there’s a possibility that Bouygues Telecom could be acquired by another telecoms operator (low-cost player, Iliad, has been mooted).

Nonetheless, for Bouygues, offloading its telecoms business bodes well – it’s been highlighted here previously and so has the fact that the other French telecoms operators stand to benefit from further consolidation in the sector.

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. CFD and Forex Trading are leveraged products and your capital is at risk. They may not be suitable for everyone. Please ensure you fully understand the risks involved by reading our full risk warning.

City Index is a trading name of StoneX Financial Ltd. Head and Registered Office: 1st Floor, Moor House, 120 London Wall, London, EC2Y 5ET. StoneX Financial Ltd is a company registered in England and Wales, number: 05616586. Authorised and regulated by the Financial Conduct Authority. FCA Register Number: 446717.

City Index is a trademark of StoneX Financial Ltd.

The information on this website is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement.

© City Index 2024